Integral Health Asset Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Integral Health Asset Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-200,000	Closed	-$14M	–	114
2026 Q1	$14M	Hold	200,000	–	–	0.67%	35
2025 Q4	$16.4M	Sell	200,000 -50,000	-20%	-$3.73M	0.81%	45
2025 Q3	$14.9M	Buy	250,000 +50,000	+25%	+$2.46M	1.01%	31
2025 Q2	$8.1M	Hold	200,000	–	–	0.74%	39
2025 Q1	$10.3M	Sell	200,000 -150,000	-43%	-$7.41M	1.09%	28
2024 Q4	$19.4M	Sell	350,000 -25,000	-7%	-$1.14M	1.65%	21
2024 Q3	$12.3M	Sell	375,000 -215,000	-36%	-$6.04M	1.39%	21
2024 Q2	$16M	Hold	590,000	–	–	1.52%	19
2024 Q1	$21.4M	Buy	590,000 +490,000	+490%	+$14.4M	1.99%	14
2023 Q4	$2.02M	Buy	+100,000	New	+$1.67M	0.28%	67

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Integral Health Asset Management's TARS Position: Q2 2026 in Review

Integral Health Asset Management sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 200,000 shares — an estimated $14M sold.

Integral Health Asset Management first reported a position in TARS in Q4 2023 and held it in 10 quarters. The position peaked at $21.4M in Q1 2024. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Integral Health Asset Management reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Integral Health Asset Management sold 200,000 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $14M.
Integral Health Asset Management first reported a position in Tarsus Pharmaceuticals in Q4 2023 and held it in 10 quarters.
Integral Health Asset Management's Tarsus Pharmaceuticals position peaked at $21.4M in Q1 2024.
256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.